Daprodustat in Dialysis (2021) — Trial Summary
Daprodustat in Dialysis (2021): ASCEND-D, a randomized, open-label phase 3 trial in 2,964 patients on dialysis with a hemoglobin of 8.0 to 11.5 g/dL, compared oral daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), with an injectable ESA (epoetin alfa on hemodialysis, da
References
- Singh AK, Carroll K, Perkovic V, et al. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021;385(25):2325-2335.